McKesson

McKesson has signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, a move investors view as expanding its oncology and multispecialty strategy. Precision Medicine Group provides clinical research services, biomarker analysis, laboratory services and commercialization support for biotech and pharma companies. The acquisition follows a restructuring that refocused McKesson on higher-margin, faster-growing areas; its oncology and multispecialty business recently grew by 33%. analyst backing and a dividend increase have supported the positive market reaction; the stock rose sharply intraday and is approaching its 52-week high. » More on de.investing.com

McKesson reported Q1 revenue of $105.4 billion and adjusted EPS of $9.93, up 20%, and raised its fiscal 2027 adjusted EPS guidance to $44.20–45.00. North American Pharmaceutical led growth, GLP-1 distribution revenue rose 24% to $15 billion, and Oncology & Prescription Technology posted double-digit operating-profit gains. The company advanced the planned separation of its Medical-Surgical Solutions business under the Wellverse name and returned $2.6 billion to shareholders while boosting the quarterly dividend by 15%. » More on finance.yahoo.com

McKesson reported adjusted EPS of $9.93 for Q1 (expectation $9.64) and revenue of $105.38 billion, both above estimates. The company raised its full-year adjusted EPS outlook to $44.20–$45.00, cited North American Pharmaceutical and Oncology & Multispecialty as growth drivers, and plans increased investment in AI. The board approved a 15% increase in the quarterly dividend; the stock rose notably in pre-market and after-hours trading. Free cash flow was negative for the quarter but improved significantly year over year. » More on de.investing.com